2. Search Result
Search Result
Results for "

SMDC

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128914
    Tubulysin

    		ADC Payload Antibiotic Microtubule/Tubulin Cancer
    The Tubulysin family of secondary metabolites was originally isolated from the myxobacteria Archangium geophyra and Angiococcus disciformis. These compounds are potent microtubule destabilizers and anti-microtubule toxins (anti-microtubule toxins), with effective IC50 concentrations against multidrug-resistant cancer cell lines. In the picomole range. Tubulysins are ideal candidates for incorporation into small active molecule conjugate (SMDC) delivery systems and are commonly used in ADC synthesis as ADC cytotoxins (ADC Cytotoxin) .
    Tubulysin
  • HY-175350
    OncoFAP-GlyPro-MMAE

    		FAP Microtubule/Tubulin Cancer
    OncoFAP-GlyPro-MMAE is a FAP small molecule-drug conjugate (SMDC) with an IC50 of 0.49  nM. OncoFAP-GlyPro-MMAE consists of a FAP Ligand OncoFAP (HY-145938), a Tubulin inhibitor (MMAE) (HY-15162) and a linker. OncoFAP-GlyPro-MMAE can be used for cancers like renal cancer research .
    OncoFAP-GlyPro-MMAE
  • HY-114306
    EC0489

    		Antifolate Cancer
    EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor . Small molecule-agent conjugate (SMDC) .
    EC0489
  • HY-175353
    TriOncoFAP-GlyPro-MMAE

    		FAP Cancer
    TriOncoFAP-GlyPro-MMAE is a small molecule drug conjugate (SMDC) targeting fibroblast activation protein (FAP) with an IC50 of 13 pmol/L. TriOncoFAP-GlyPro-MMAE combines a FAP-targeting ligand (TriOnco), a cleavable glycine-proline linker, and a cytotoxic payload (MMAE) .
    TriOncoFAP-GlyPro-MMAE
  • HY-164429
    VIP236

    		Integrin Elastase Cancer
    VIP236 is a small-molecule-drug conjugates (SMDCs) consisting of an αvβ3 integrin binder linked to an optimized Camptothecin (HY-16560) topoisomerase I (TOP1) inhibitor payload. VIP236 exerts anticancer activity by targeting αvβ3 integrins, and it can release payload upon cleavage by neutrophil elastase in the tumor microenvironment .
    VIP236
  • HY-169336
    CQ-16

    		PARP PSMA Cancer
    CQ-16 is an orally active small molecule drug conjugate (SMDC) targeting prostate-specific membrane antigen (PSMA). CQ-16 exhibits highly selective antiproliferative activity between PSMA-positive and PSMA-negative prostate cells. In addition, CQ-16 also has PARP inhibitory activity (IC50=1 nM). (Pink: PSMA Ligand (HY-139840); Black: Linker (HY-W037980); Blue: PARP Inhibitor (HY-10162))
    CQ-16

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: